KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for BeOne Medicines (ONC) over the last 3 years, with Q4 2017 value amounting to $268750.0.

  • BeOne Medicines' Gains from Sales and Divestitures rose 50467.99% to $268750.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $268750.0, marking a year-over-year increase of 50467.99%. This contributed to the annual value of $268750.0 for FY2017, which is 50467.99% up from last year.
  • Latest data reveals that BeOne Medicines reported Gains from Sales and Divestitures of $268750.0 as of Q4 2017, which was up 50467.99% from $44445.0 recorded in Q4 2016.
  • BeOne Medicines' Gains from Sales and Divestitures' 5-year high stood at $533333.0 during Q4 2015, with a 5-year trough of $44445.0 in Q4 2016.
  • Its 3-year average for Gains from Sales and Divestitures is $282176.0, with a median of $268750.0 in 2017.
  • Per our database at Business Quant, BeOne Medicines' Gains from Sales and Divestitures plummeted by 9166.66% in 2016 and then surged by 50467.99% in 2017.
  • Over the past 3 years, BeOne Medicines' Gains from Sales and Divestitures (Quarter) stood at $533333.0 in 2015, then tumbled by 91.67% to $44445.0 in 2016, then surged by 504.68% to $268750.0 in 2017.
  • Its Gains from Sales and Divestitures was $268750.0 in Q4 2017, compared to $44445.0 in Q4 2016 and $533333.0 in Q4 2015.